Frequency Therapeutics (NASDAQ:FREQ) is reducing its workforce by 55% and abandoning programs in Sensorineural Hearing Loss (SNHL) after FX-322 failed to meet the main goal of a phase 2b study in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback